High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.65B
+1.1%
1.883
-0.87%
7.04B
+5.53%
2.050
+13.26%
7.49B
+5.76%
2.227
+10.8%
Estimates Revision
The market is revising Upward the revenue expectations for Gilead Sciences, Inc. (GILD) for FY2025, with the revenue forecasts being adjusted by 0.01% over the past three months. During the same period, the stock price has changed by 8.73%.
Revenue Estimates for FY2025
Revise Upward
+0.01%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+8.73%
In Past 3 Month
20 Analyst Rating
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 133.83 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 122.620
Low
105.00
Averages
133.83
High
150.00
Current: 122.620
Low
105.00
Averages
133.83
High
150.00
Truist
Gregory Renza
Buy
downgrade
$145 -> $140
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$145 -> $140
2025-11-24
downgrade
Buy
Reason
Truist analyst Gregory Renza assumed coverage of Gilead with a Buy rating with a price target of $140, down from $145. The firm is positive on the continued strength for the company's HIV franchise, supported by Biktarvy's patent settlement and positive momentum across next-generation programs,most notably Yeztugo's PrEP launch and Bic/Len's positive phase 3 readout, pointing to a healthy outlook into the next-decade, the analyst tells investors in a research note. Truist adds that it also views the oncology franchise as a key growth pillar led by Trodelvy and anito-cel, further noting that Livdelzi's launch in PBC - Primary Biliary Cholangitis - is off to a strong start.
BMO Capital
BMO Capital
Outperform
maintain
$135
2025-11-24
Reason
BMO Capital
BMO Capital
Price Target
$135
2025-11-24
maintain
Outperform
Reason
BMO Capital says Phase 1 data from three patients in Kelonia Therapeutics' inMMyCAR study "look interesting," with all patients reaching MRD negativity by month one, but adds that the extremely small sample size and limited amount of patient follow-up "muddies comparisons" to Gilead (GILD) and Arcellx's (ACLX) anito-cel program. The tolerability profile of Kelonia's KLN-1010 "looks relatively clean," but the small sample size and the limited amount of patient follow-up "leave significant questions," adds the analyst, who keeps an Outperform rating and $135 price target on Gilead shares.
Mizuho
Outperform
maintain
$131 -> $140
2025-11-20
Reason
Mizuho
Price Target
$131 -> $140
2025-11-20
maintain
Outperform
Reason
Mizuho raised the firm's price target on Gilead to $140 from $131 and keeps an Outperform rating on the shares. The firm raised its price target primarily due to: Biktarvy's loss of exclusivity in the U.S. now expected to be 2036 instead of 2033 post generic lititgation settlements; the total addressable market for PrEP could be much larger than currently appreciated, and; the firm now models roughly 5% growth for Gilead's HIV business overall, from roughly 3% prior.
Scotiabank
NULL -> Outperform
initiated
$140
2025-11-12
Reason
Scotiabank
Price Target
$140
2025-11-12
initiated
NULL -> Outperform
Reason
Scotiabank initiated coverage of Gilead with an Outperform rating and $140 price target.
Truist
Asthika Goonewardene
Buy
maintain
$127 -> $145
2025-11-02
Reason
Truist
Asthika Goonewardene
Price Target
$127 -> $145
2025-11-02
maintain
Buy
Reason
Truist analyst Asthika Goonewardene raised the firm's price target on Gilead to $145 from $127 and keeps a Buy rating on the shares. The company's Q3 results supports the view of a stable base business, but while HIV remains the primary driver with improving PrEP execution, oncology results were mixed and cell therapy continues to face competitive pressure despite broader site access, the analyst tells investors in a research note.
JPMorgan
Chris Schott
Overweight
maintain
$145 -> $150
2025-10-31
Reason
JPMorgan
Chris Schott
Price Target
$145 -> $150
2025-10-31
maintain
Overweight
Reason
JPMorgan analyst Chris Schott raised the firm's price target on Gilead to $150 from $145 and keeps an Overweight rating on the shares post the Q3 report. The firm says the Yeztugo launch is off to an "encouraging start."
See All Ratings
Valuation Metrics
The current forward P/E ratio for Gilead Sciences Inc (GILD.O) is 14.59, compared to its 5-year average forward P/E of 11.52. For a more detailed relative valuation and DCF analysis to assess Gilead Sciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Overvalued
5Y Average PE
11.52
Current PE
14.59
Overvalued PE
14.14
Undervalued PE
8.90
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
8.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.86
Undervalued EV/EBITDA
7.24
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.68
Current PS
0.00
Overvalued PS
4.27
Undervalued PS
3.09
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 606.95% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 606.95% over the last month.
Sold
Bought
GILD News & Events
Events Timeline
(ET)
2025-11-21
12:57:16
Gilead's Kite Pharma Receives Orphan Status for Multiple Myeloma Therapy
2025-11-18 (ET)
2025-11-18
05:06:55
Gilead Reveals Initial Shipments of Lenacapavir to Eswatini and Zambia
2025-11-13 (ET)
2025-11-13
09:55:01
Significant Early Gainers in Liquid Options on November 13th
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/0c4ac78b88a5c61c284cc22f01cd56acf996203351c97a57c3d88790e524889e.jpg)
Preview
4.5
12-04NASDAQ.COMETF Outflow Warning: FDMO, KLAC, NET, GILD
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b31d0210335593f5e90626ed65779435253ebe1acfa082479124493ce448cb96.png)
Preview
6.5
12-02Barron's16 Strong Stocks to Hold During Market Volatility
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4fef9d1ab00f58dd3f2f083d106a7d6df71adc63607be3c24b7fb1ce2dde2ae4.jpg)
Preview
3.0
11-28NASDAQ.COMBristol Myers or Gilead Sciences: Which Biotech Stock Is the Superior Investment Today?
Sign Up For More News
People Also Watch
FAQ
What is Gilead Sciences Inc (GILD) stock price today?
What is Gilead Sciences Inc (GILD)'s business?
What is the price predicton of GILD Stock?
What is Gilead Sciences Inc (GILD)'s revenue for the last quarter?
What is Gilead Sciences Inc (GILD)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Gilead Sciences Inc (GILD)'s fundamentals?
How many employees does Gilead Sciences Inc (GILD). have?